Artificial intelligence is significantly advancing cancer research and patient care. Uppsala University researchers developed AI models that detect prostate cancer cases missed by pathologists by identifying subtle tissue changes. Meanwhile, Tempus AI acquired digital pathology firm Paige in an $81 million deal to enhance its dataset and AI capabilities for oncology. Additionally, computational approaches have uncovered Bufalin as a new estrogen receptor degrader, highlighting AI's role in accelerating drug discovery against hormone-responsive cancers.